North America Pen Needles Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Pen Needles Market Size

• The North America Pen Needles market size was valued at USD 625 million in 2024 and is expected to reach USD 1.07 billion by 2032, at a CAGR of 7.0% during the forecast period
• This growth is driven by the increasing prevalence of diabetes, advancements in pen needle technology, and a growing preference for self-administration of injectable therapies.

Pen Needles Market Analysis

• Pen needles are essential components for delivering injectable medications, particularly insulin, in a convenient and minimally invasive manner. The North American market is experiencing significant growth due to rising diabetes incidence, technological advancements in needle design, and increased patient awareness.
• The demand for pen needles is significantly driven by the growing diabetic population, favorable reimbursement policies, and the convenience offered by pen devices over traditional syringes.
• The United States is expected to dominate the North America Pen Needles market due to its advanced healthcare infrastructure, high adoption of insulin pens, and presence of key market players.
• Canada is expected to witness the highest CAGR in the Pen Needles market due to increasing diabetes prevalence, supportive government initiatives, and rising awareness about diabetes management.
• Standard Pen Needles segment is expected to hold the largest share of 60.5%, due to their widespread use, cost-effectiveness, and compatibility with a variety of pen devices.

Report Scope and Pen Needles Market Segmentation

Pen Needles Market Trends

“Adoption of Safety Pen Needles and Technological Advancements”

• The market is witnessing a shift towards safety pen needles that reduce the risk of needlestick injuries and promote user safety. Manufacturers are focusing on ergonomics and material innovations to make injections less painful and more reliable for chronic conditions such as diabetes.
  • For instance, Terumo Corporation introduced a safety pen needle that automatically retracts post-injection, reducing the chances of accidental pricks. Simultaneously, BD and Novo Nordisk have invested in ultra-thin gauge technologies, with BD’s 2025 launch of its 4mm ultra-fine needle gaining traction among insulin-dependent patients for its improved comfort.

Pen Needles Market Dynamics

“Rising Prevalence of Diabetes and Preference for Self-Administration”

• The growing burden of diabetes across North America is driving the adoption of convenient insulin delivery options, particularly pen devices. Patients increasingly prefer pen needles over conventional syringes due to their simplicity, portability, and reduced injection pain, which enhances treatment compliance and outcomes.
  • For instance, the CDC reported over 37 million diabetes cases in the U.S. in 2023. The American Diabetes Association highlighted that the use of self-administered insulin pens with compatible pen needles improved adherence in both pediatric and elderly populations.
• The increasing incidence of diabetes in North America is a primary driver for the pen needles market. According to the CDC, over 37 million people in the U.S. had diabetes in 2023, driving demand for daily insulin injections. Patients prefer pen devices for their ease of use, portability, and minimal pain, leading to higher adoption rates. The American Diabetes Association reports that self-administered insulin pens with compatible pen needles have increased medication adherence, particularly among elderly and pediatric patients.

Opportunity

“Growth of Online Pharmacies and E-commerce Platforms”

• The rise of digital health platforms and e-commerce infrastructure is enhancing access to pen needles, particularly among tech-savvy and rural populations. Online availability supports flexible purchasing models, including subscriptions and bulk ordering, which cater to the needs of chronic disease patients.
  • For instance, Embecta launched an e-commerce portal in 2025, enabling direct-to-consumer sales of pen needles across the U.S., streamlining access and reducing reliance on traditional pharmacies.
• The expansion of online pharmacies offers patients easier access to pen needles, often at competitive prices. For instance, Embecta’s 2025 launch of its dedicated e-commerce portal in the U.S. allowed patients to order pen needles directly, reducing dependency on physical retail chains. This trend is expected to boost market growth, especially among the tech-savvy population seeking doorstep delivery and subscription-based medication refill models.

Restraint/Challenge

“High Cost of Advanced Pen Needles”

• While advanced safety features such as retraction mechanisms and single-use locks improve user safety, they also increase production costs. This cost is often passed on to the consumer, making such products less affordable for the uninsured or underinsured population.
  • For instance, a 2024 study by the National Diabetes Association found that 28% of insulin-dependent patients delayed needle purchases due to cost concerns, particularly among those not covered by insurance.
• The cost of safety and technologically advanced pen needles can be a barrier for some patients, particularly those without adequate insurance coverage. A 2024 study by the National Diabetes Association revealed that 28% of insulin-dependent patients in North America delayed or reduced needle purchases due to out-of-pocket expenses. Advanced safety mechanisms, such as automatic retraction or single-use locks, raise manufacturing costs, thereby making these devices less accessible for the uninsured segment.

Pen Needles Market Scope

The market is segmented on the basis of product type, needle length, therapy, mode of purchase, end user, and distribution channel.

In 2025, the Standard Pen Needles segment is projected to dominate the market with the largest share in product type segment

In 2025, the Standard Pen Needles segment is expected to hold the largest share of 60.5%, due to their widespread use, cost-effectiveness, and compatibility with various pen devices. Expanding preferences for cost-efficient insulin delivery devices in the U.S. and availability of these products across retail chains are supporting market dominance.

The Insulin Therapy segment is expected to account for the largest share during the forecast period in therapy segment

In 2025, the Insulin Therapy segment is anticipated to capture a 70.2% share, driven by the high prevalence of diabetes and the necessity for regular insulin administration. Increasing insulin-dependent diabetic population and rapid shift toward self-managed diabetes therapies have boosted segment growth.Pen Needles Market Regional Analysis

“United States Holds the Largest Share in the Pen Needles Market”

The United States is expected to dominate the North America Pen Needles market due to its advanced healthcare infrastructure, high adoption of insulin pens, and presence of key market players.

Additionally, increased awareness campaigns on diabetes management, high spending on healthcare, and early product adoption trends contribute to the U.S. lead.

“Canada is Projected to Register the Highest CAGR in the Pen Needles Market”

Canada is expected to witness the highest CAGR in the Pen Needles market due to increasing diabetes prevalence, supportive government initiatives, and rising awareness about diabetes management.

Ongoing partnerships between government and device companies and expansion of telemedicine platforms also enable greater access to advanced pen needle solutions.

Pen Needles Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• BD (Becton, Dickinson and Company) (U.S.)
• Novo Nordisk (Denmark)
• Ypsomed AG (Switzerland)
• Sanofi (France)
• Terumo Corporation (Japan)
• Owen Mumford Ltd. (U.K.)
• Embecta Corp. (U.S.)
• Allison Medical, Inc. (U.S.)
• UltiMed, Inc. (U.S.)
• Arkray USA, Inc. (U.S.)

Latest Developments in North America Pen Needles Market

• In January 2025, BD announced the commercial availability of its next-generation 4mm ultra-thin pen needle in the U.S., focusing on pain-free insulin delivery.
• In February 2025, Novo Nordisk expanded its diabetes care outreach program in Canada, distributing pen needle starter kits to newly diagnosed patients.
• In March 2025, Embecta launched an e-commerce portal offering direct-to-consumer sales of pen needles across North America.
• In April 2025, Terumo Corporation partnered with U.S. health systems to pilot a safety pen needle design aimed at reducing needlestick injuries among home users.

SKU-46165